제목: Review of continuous process development in SK biotek

내용: Over the past decade, the Continuous Process has become of increasing importance within the pharmaceutical industry, whether it is in drug product processing or drug substance production. Due to its many benefits compared to the classic batch process, the continuous process offers higher process safety, a reduced environmental footprint, and a more efficient scale-up.

The issue that is posed by the Continuous Process is developing it from the R&D approach to commercial usage. The Continuous Process that we, at SK biotek, have developed, utilizes our expertise in the industrial refinery process, built-up over the past 50 years, including automated and closed manufacturing systems, chemical conversion, catalytic process, and purification. Amongst the many innovative solutions we have developed, I will be discussing two of the main developmental pathways: Continuous Tubular Reactions (Static mixer type) and Continuous Catalytic Reactions (Fixed bed type). Key achievements of our Continuous Tubular Process, including organometallic reactions and hazardous reactions, will be briefly discussed from their inception in R&D development to their usage in the commercial stage.

A key factor is, our in-house capability to design and produce new catalysts, that allow for new continuous catalytic reactions such as selective nitro hydrogenation, Rosenmund reduction, lactam reduction, and reductive debromination will also be enumerated upon. Through these new catalysts, we have created new processes that can act as alternatives to those used in today’s industries that require the use of rare metals, driving down production costs as their rapidly increasing price becomes a non-factor.